Lithium News and Research

RSS

Antiepileptic drugs may have a possible protective effect against seizure disorders

Despite government warnings about an increased risk of suicidal thoughts and actions while taking antiepileptic drugs, these medications do not appear to be associated with increased risk of suicide attempts in individuals with bipolar disorder, and may have a possible protective effect, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

New smoke free, electronic cigarettes from Smart Fixx

If you or someone you know wants an alternative to smoking this year, Smart Fixx smokeless electronic cigarettes may be the perfect solution. Also known as electric cigarettes and vapor cigarettes, these smoke free cigs give smokers three big incentives for making this New Year’s resolution stick!

7 Dec 2009

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.

21 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Saft, the world specialist in the design and manufacture of high-tech batteries for industry, has expanded its range of lithium technologies with the VL 10V Fe Super-Phosphate(TM), the highest power lithium iron phosphate cell on the market. These large cells are designed for defense applications, such as U.S. Navy undersea operations, requiring very high power and safe operation.

2 Nov 2009

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

ADA Technologies to develop home lithiummonitor for patients with bipolar disorder

ADA Technologies, Inc. (ADA) received a $189,886 grant from the National Institute of Mental Health to develop a home lithiummonitor for use by patients with bipolar disorder.

26 Oct 2009

ECA commends Governor Schwarzenegger's stance on alternative smoking devices

Matt Salmon, president of the Electronic Cigarette Association (ECA), today praised California Governor Schwarzenegger’s wise decision to veto Senate Bill 400, which would have banned electronic cigarette sales in the state, protecting adult consumers’ access to these alternative smoking devices.

13 Oct 2009

U.S. Army renews mPhase Technologies' Phase II STTR grant

mPhase Technologies, Inc. announced today that their Phase II STTR Grant was renewed by the U.S. Army. The two year grant was initially awarded in September 2008 for the amount of $750,000. mPhase will continue to develop the Smart NanoBattery under this grant program through September 2010.

8 Oct 2009

Study shows that GSK-3 gene determines the total number of neurons required for brain

In populating the growing brain, neural stem cells must strike a delicate balance between two key processes - proliferation, in which the cells multiply to provide plenty of starting materials - and differentiation, in which those materials evolve into functioning neurons.

5 Oct 2009

JDSU announces key advancements in complete portfolio of tunable solutions

JDSU (NASDAQ: JDSU) (TSX: JDU) today announced key advancements as part of its strategy to offer a complete portfolio of tunable solutions in multiple form factors for use within DWDM networks.

21 Sep 2009

WillWalk to raise funds for human stem cell trials for people with SCI

WillWalk, an Austin based non-profit organization has committed itself to be at the forefront of ending Paralysis. WillWalk will raise $3 million to help fund the first non-controversial human stem cell trials for people with Spinal Cord Injury (SCI).

14 Sep 2009

Scientists harness carbon nanomaterials for drug delivery, oxygen sensors

Two nanoscale devices recently reported by University of Pittsburgh researchers in two separate journals harness the potential of carbon nanomaterials to enhance technologies for drug or imaging agent delivery and energy storage systems, in one case, and, in the other, bolster the sensitivity of oxygen sensors essential in confined settings, from mines to spacecrafts.

17 Aug 2009

New findings on how lithium may help radiation target cancer

Vanderbilt-Ingram Cancer Center investigators have uncovered a mechanism that helps explain how lithium, a drug widely used to treat bipolar mood disorder, also protects the brain from damage that occurs during radiation treatments.

4 May 2009

Scientists suggest a mechanism for how lithium works in bipolar treatment

Lithium has been established for more than 50 years as one of the most effective treatments for bipolar mood disorder.

22 Apr 2009

Seroquel XR supplemental NDA recommended for approval

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for Seroquel XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

9 Apr 2009

Schizophrenia gene found to control the birth of new neurons

A gene that is arguably the most studied "schizophrenia gene" plays an unanticipated role in the brain: It controls the birth of new neurons in addition to their integration into existing brain circuitry, according to a report in the March 20th issue of the journal Cell, a Cell Press publication.

20 Mar 2009